Current
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
MMWR: October 20, 2023 / 72(42);1140–1146
-
RSV (Respiratory Syncytial Virus)
Current
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
MMWR, October 13, 2023, 72(41);1115-1122
-
PCV (Pneumococcal Conjugate)
-
Pneumococcal
Current
ACIP Updates: Recommendations for Use of 20-Valent Pneumococcal Conjugate Vaccine in Children ― United States, 2023
MMWR. 2023 / 72(39);1072
Archived
COVID-19 Vaccination Recommendations and Practices for Women of Reproductive Age by Health Care Providers — Fall DocStyles Survey, United States, 2022
MMWR: September 29, 2023 / 72(39);1045–1051
-
PCV (Pneumococcal Conjugate)
-
Pneumococcal
-
PPSV (Pneumococcal Polysaccharide)
Current
Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023.
MMWR. 2023 / 72(RR-3);1–39
Current
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023–24 Influenza Season
MMWR; August 25, 2023;72(RR-2);1-25
-
RSV (Respiratory Syncytial Virus)
Current
Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023
MMWR, August 25, 2023, 72(34); 920–925
-
RSV (Respiratory Syncytial Virus)
Current
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices
MMWR, July 21, 2023, 72 (29); 793-801
Archived
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
MMWR: June 16, 2023 / 72(24);657–662
Current
Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
MMWR, November 18, 2022, 71 (46); 1465-1470
Archived
ACIP Interim Recommendations for the Use of Bivalent Booster Doses of COVID-19 Vaccines—United States, October 2022
MMWR, November 11, 2022, 71(45);1436-1441
Current
Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices, 2022
MMWR, September 30, 2022, 71 (2); 1-8
Current
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022
MMWR, September 16, 2022, 71(37);1174–1181
Archived
Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022–23 Influenza Season
MMWR, August 26, 2022, 71(1); 1-28
Archived
ACIP Interim Recommendation for Use of the Novavax COVID-19 Vaccine in Adults 18 years and older — US, July 2022
MMWR, August 5, 2022, 71(31);988–992
Archived
ACIP Interim Recommendations for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
MMWR Early Release June 28, 2022
-
Mpox (Monkeypox)
-
Smallpox
Current
Use of Jynneos (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — US, 2022
MMWR, May 27, 2022, Vol 71
Current
Use of a Modified Preexposure Prophylaxis Vaccination Schedule to Prevent Human Rabies: Recommendations of the Advisory Committee on Immunization Practices — US, 2022
MMWR, May 6, 2022, 71(18);619–627
Current
Universal Hepatitis B Vaccination in Adults Aged 19–59 Years, updated ACIP recommendations
MMWR, April 1, 2022, 71(13);477–483
Archived
ACIP Recommendation for use of Moderna COVID-19 Vaccine in Adults aged 18 years and older, considerations for extended intervals for primary series doses of mRNA COVID-19 vaccines — US, February 2022
MMWR, March 18, 2022, 71 (11); 416-421
